14 Recruiting Hairy Cell Leukemia Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Hairy Cell Leukemia
Top Recruiting Hairy Cell Leukemia Studies
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
📍 Yale University — New Haven, Connecticut
View Study & Checklist ➔Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
📍 NCI - Center for Cancer Research — Bethesda, Maryland
View Study & Checklist ➔Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔